# Mavrostobart

Source: https://onco.cc/drugs/mavrostobart/  
OnCo record `mavrostobart` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mavrostobart is an experimental monoclonal antibody from Phanes Therapeutics in phase 2 trials for non-small-cell lung cancer and pancreatic ductal adenocarcinoma, aimed at CD73 / adenosine axis.

## Summary

Mavrostobart (PT199) is a monoclonal antibody developed by Phanes Therapeutics. Its target is CD73 / adenosine axis. ClinicalTrials.gov describes the intervention as: Mavrostobart (PT199) is an anti-CD73 mAb with a differentiated mechanism of action. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and pancreatic ductal adenocarcinoma. The largest, NCT05431270, plans to enrol 40 participants with primary completion expected 2027-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Also known as: Mavrostobart (PT199)
- Tags: pipeline; ctgov-ingest
- Code: PT199
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody directed at CD73 / adenosine axis, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.

## Sources

- ClinicalTrials.gov: trials of Mavrostobart: https://clinicaltrials.gov/search?intr=PT199

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [CD73 / adenosine axis](https://onco.cc/targets/cd73-adenosine/)
- companies: [Phanes Therapeutics](https://onco.cc/companies/phanes-therapeutics/)
- trials: [Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy](https://onco.cc/trials/nct05431270/)

---
JSON: https://onco.cc/api/v1/entities/mavrostobart.json